MedTrace Logo

GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance

NCT01381328 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2013-02-11

No results posted yet for this study

Summary

The purpose of this study is to correlate the different patterns of resistance mutations observed in vivo in patients failing RAL treatment with the fold-change resistance determined by the phenotypic assay.

Conditions

  • HIV-1 Infected Patients
  • Fold-change Resistance
  • Resistance Mutations

Sponsors & Collaborators

  • IRCCS San Raffaele

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Università Vita-Salute San Raffaele

    lead OTHER

Principal Investigators

  • Massimo Clementi, Prof. · University Vita-Salute San Raffaele Laboratory of Microbiology and Virology

  • Antonella Castagna, MD · Department of Infectious Diseases, IRCCS San Raffaele Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-03-31
Completion
2013-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381328 on ClinicalTrials.gov